{"id":8324,"date":"2006-02-11T18:12:40","date_gmt":"2006-02-11T18:12:40","guid":{"rendered":"http:\/\/i-base.info\/htb\/?p=8324"},"modified":"2013-12-07T08:17:22","modified_gmt":"2013-12-07T08:17:22","slug":"efficacy-of-lopinavirr-in-patients-with-advanced-hiv-cd4-25-cellsmm3","status":"publish","type":"post","link":"https:\/\/i-base.info\/htb\/8324","title":{"rendered":"Efficacy of lopinavir\/r in patients with advanced HIV (CD4 <25 cells\/mm3)"},"content":{"rendered":"<p><strong>Simon Collins, HIV i-Base<\/strong><\/p>\n<p><strong>An analysis from four randomised studies of lopinavir\/r, that stratified patients by baseline CD4, showed that comparable results were achieved by patients even with the most advanced HIV defined as CD4 counts &lt;25 cells\/mm<sup>3<\/sup> and\/or viral load &gt;300,000 copies\/mL (comprising 11% and 21% of the pooled study populations respectively).<\/strong><\/p>\n<p>No significant differences were seen in the proportion of patients with viral load &lt;50 copies\/mL at week 48 by intent-to-treat analysis, when looking at either baseline CD4 or viral load. There were also no significant differences in time to loss of virological response (TLVR).<\/p>\n<p>Using CD4 &gt;500 cells\/mm<sup>3<\/sup> as a reference, the hazard ratio\u0092s (95% CI) for TLVR were 0.7 (0.3-1.4), 0.6 (0.3-1.2), 0.7 (0.3.1.3) 0.8 (0.3-1.9) and 1.0 (0.5-2.1) in patients with baseline CD4 counts of 350-488, 200-348, 50-99, 25-49 and &lt;25 cells\/mm<sup>3<\/sup> respectively. In the analysis of baseline viral load, using &lt;30,000 as the reference, HR (95%CI) were 0.9 (0.5-1.6), 1.3 (0.7-2.2) and 0.8 (0.4, 1.6) in patients with baseline levels of 30-100k, 100-300k and &gt;300k respectively.<\/p>\n<p>CD4 responses were generally comparable by baseline group, with 44% and 63% of those with baseline counts &lt;25 and 25-49 cells\/mm<sup>3<\/sup> respectively increasing to &gt;200 cells\/mm<sup>3<\/sup> at week 48.<\/p>\n<p>Reference:<\/p>\n<p>King M, Johnson M, Youle M et al. Antiviral activity of lopinavir\/ritonavir-based regimens in subjects with CD4 counts below 25 cells\/mm<sup>3<\/sup>. 10th EACS, Dublin 2005. Poster PE7.3\/4.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Simon Collins, HIV i-Base An analysis from four randomised studies of lopinavir\/r, that stratified patients by baseline CD4, showed that comparable results were achieved by patients even with the most advanced HIV defined as CD4 counts &lt;25 cells\/mm3 and\/or viral &hellip;<\/p>\n","protected":false},"author":4,"featured_media":0,"comment_status":"open","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[4,3],"tags":[70],"class_list":["post-8324","post","type-post","status-publish","format-standard","hentry","category-conference-reports","category-antiretrovirals","tag-eacs-10th-2005"],"_links":{"self":[{"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/posts\/8324","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/comments?post=8324"}],"version-history":[{"count":0,"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/posts\/8324\/revisions"}],"wp:attachment":[{"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/media?parent=8324"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/categories?post=8324"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/tags?post=8324"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}